PlainPharmaWatch

CMS Open Payments · Program Year 2024

BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. reported $326,053.24 in payments to 188 physicians and teaching hospitals across 188 transactions.

See the rankings → How this is sourced
$326.1K
Total payments
188
Transactions
188
Recipients
+$31.9K
General Payments vs PY2023

BioCryst Pharmaceuticals, Inc. reported $326,053.24 in payments to 188 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #875 of 1,925 reporting manufacturers (0.0% of all US industry payments), averaging $1.7K per recipient across 4 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the editorial team.

The verdict

BioCryst Pharmaceuticals, Inc. pairs above-median payment volume with a broadly spread payment pattern across many recipients.

#875
of 1,925 companies
0.0%
of all US industry payments
0.2%
paid to its single top recipient
4
payment categories

Release-over-release change

General Payments changed from PY2023 to PY2024

BioCryst Pharmaceuticals, Inc.'s CMS-reported General Payments increased by $31.9K (+10.8%) from PY2023 to PY2024. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.

CMS source labels for this exact identifier: PY2022: BIOCRYST PHARMACEUTICALS, INC.PY2023: BIOCRYST PHARMACEUTICALS, INC.PY2024: BioCryst Pharmaceuticals, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$294.2KPY2024$326.1K
PY2023
$294,187.70
PY2024
$326,053.24

How BioCryst Pharmaceuticals, Inc. ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

BioCryst Pharmaceuticals, Inc.'s total vs. every reporting company

CMS Open Payments, Program Year 2024

$326,053 Top 45% higher than 55% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). Below this entry. $25,112–$78,003: 249 reporting companies (13%). Below this entry. $78,003–$242,294: 295 reporting companies (15%). Below this entry. $242,294–$752,621: 270 reporting companies (14%). This entry sits in this band. $752,621–$2,337,813: 263 reporting companies (14%). Above this entry. $2,337,813–$7,261,783: 200 reporting companies (10%). Above this entry. $7,261,783–$22,556,757: 133 reporting companies (7%). Above this entry. $22,556,757–$70,066,439: 45 reporting companies (2%). Above this entry. $70,066,439–$217,642,369: 26 reporting companies (1%). Above this entry. $217,642,369–$676,046,922: 13 reporting companies (1%). Above this entry. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for BioCryst Pharmaceuticals, Inc.

Averaging $1.7K per transaction and $1.7K per recipient, BioCryst Pharmaceuticals, Inc.'s Program Year 2024 total comes to $326,053.24 across 188 transactions and 188 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #875 of 1,925 companies, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

The 4-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $171.1K, accounting for 52.5% of the company's reported total and 92 transactions.

General Payment Breakdown by Type

BioCryst Pharmaceuticals, Inc. made 4 types of general payments. "Consulting Fee" is the largest category at $171.1K, 52.5% of the company's reported total.

How BioCryst Pharmaceuticals, Inc. divides its payments

Ranked by total dollars reported per category

1. Consulting Fee$171.1K2. Compensation for Services…$136.9K3. Travel and Lodging$16.4K4. Food and Beverage$1.7K
Payment Type Amount Transactions
Consulting Fee $171.1K 92
Compensation for Services Other Than Consulting $136.9K 37
Travel and Lodging $16.4K 36
Food and Beverage $1.7K 23

Recipient Concentration in General Payments

The five largest recipient relationships account for $201,916.83 (61.9%) of $326,053.24 in this company's General Payments records across 67 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for BioCryst Pharmaceuticals, Inc.

The five named recipients with the highest reported General Payments from this company

Steven Galson$69.1KAmy Mckee$66.7KWendy Yee$32.8KAmer Zeidan$21.0KDonald Fong$12.3K
  1. 1

    Steven Galson

    $69,146.39 across 17 reported transactions

  2. 2

    Amy Mckee

    $66,666.01 across 19 reported transactions

  3. 3

    Wendy Yee

    $32,834.85 across 5 reported transactions

  4. 4

    Amer Zeidan

    $21,000.00 across 1 reported transactions

  5. 5

    Donald Fong

    $12,269.58 across 3 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Payment Size Analysis

Average transaction size: $1.7K. Average per recipient: $1.7K.

Total Amount

$326,053.24

Avg per Transaction

$1.7K

Avg per Recipient

$1.7K

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

BioCryst Pharmaceuticals, Inc. Share

0.0%

#875 by total payments

Companies with Similar Payment Volumes

Pharmaceutical companies with payment totals similar to BioCryst Pharmaceuticals, Inc.

Brainsway USA INC

$326.1K 242 recipients

Endogastric Solutions, Inc

$325.4K 933 recipients

DeGen Medical, Inc.

$324.9K 204 recipients

Life Spine, Inc.

$327.4K 429 recipients

AMAG Pharmaceuticals, Inc.

$327.8K 8 recipients

MedAlliance LLC

$323.3K 0 recipients

Frequently Asked Questions

How much did BioCryst Pharmaceuticals, Inc. pay to physicians and hospitals in 2024? ▾
In Program Year 2024, CMS Open Payments recorded $326,053.24 from BioCryst Pharmaceuticals, Inc. to physicians and hospitals across 188 transactions - 0.0% of all industry payments reported that year.
How many physicians received payments from BioCryst Pharmaceuticals, Inc.? ▾
Averaging $1.7K per recipient, BioCryst Pharmaceuticals, Inc.'s 2024 payments reached 188 physicians and teaching hospitals.
What types of payments did BioCryst Pharmaceuticals, Inc. make? ▾
General payments from BioCryst Pharmaceuticals, Inc. span 4 distinct categories, covering things like consulting, meals, and travel. The largest general-payment category was "Consulting Fee" at $171.1K, representing 52.5% of the company's reported total.
How does BioCryst Pharmaceuticals, Inc. rank among pharmaceutical companies? ▾
Out of 1,925 companies in the CMS Open Payments database for 2024, BioCryst Pharmaceuticals, Inc. ranks #875 by total payment amount.
What is the average payment size from BioCryst Pharmaceuticals, Inc.? ▾
BioCryst Pharmaceuticals, Inc.'s 188 transactions to 188 recipients in 2024 averaged $1.7K per transaction.
Where does the payment data for BioCryst Pharmaceuticals, Inc. come from? ▾
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download BioCryst Pharmaceuticals, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.